Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) receptor , is demonstrating promising data in initial clinical studies. Current examination https://bookmarkhard.com/story21378513/retatrutide-emerging-research-and-potential-therapeutic-roles